# David Wild

פרקי פודקאסט מובילים
מְעוּדכָּן:

Sonny and Natalia + Joel McHale (Carolla Classics)

#1 ACS #796 (feat. Sonny Carolla, Natalia Carolla, Dr. Drew, Alison Rosen and Bryan Bishop) Recorded 04-06-2012 – Release Date 04-09-2012 #2 ACS #798 (feat. David Wild, Oriol Servia, Alison Rosen and Bryan Bishop) Recorded 04-09-2012 – Release Date 04-10-2012 #3 ACS #2038 (feat. Eric Stonestreet‮…

Sonny and Natalia + Joel McHale (Carolla Classics)

· תמליל
#1 ACS #796 (feat. Sonny Carolla, Natalia Carolla, Dr. Drew, Alison Rosen and Bryan Bishop)Recorded 04-06-2012 – Release Date 04-09-2012#2 ACS #798 (feat. David Wild, Oriol Servia, Alison Rosen and Bryan Bishop)Recorded 04-09-2012 – Release Date 04-10-2012#3 ACS #2038 (feat. Eric Stonestreet, Lyne‮…

Michelle Branch + Teresa Strasser (Carolla Classics)

#1 ACS #874 (feat. Colin Mochrie, Michelle Branch, David Wild, Alison Rosen and Bryan Bishop) (2012) #2 ACS #829 (feat. Teresa Strasser, Alison Rosen and Bryan Bishop) (2012) #3 ACS #2443 (feat. Wheeler Walker Jr., Jo Koy, Gina Grad and Bryan Bishop) Recorded 10-30-2018 – Release Date 10-31-2018‮…

Strategic Intent: How Circio Rebuilt Itself Around Circular RNA

Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both. Three and a half years ago, Circio ended its legacy oncolytic virus and cancer vaccine programs and pivoted to circular RNA, while ‮…

S05 Episode 14: Rise Up - Springsteen's 2nd Night In LA (with David Wild)

In the latest episode of None But The Brave, co-hosts Hal Schwartz and Flynn McLean are joined by David Wild, longtime Rolling Stone writer as well as writer/producer of The Grammys and co-host of the Naked Lunch podcast, to discuss Bruce Springsteen & The E Street's second show on the 2024 tour i‮…

Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine?

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moder‮…

Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine?

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moder‮…

Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine?

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moder‮…

Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power

Conventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David Wild talks with Harris Kaplan (managing partner, Litmys), Sal Grouso (senior market access executive), and Roxanne Schwans‮…

Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power

Conventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David Wild talks with Harris Kaplan (managing partner, Litmys), Sal Grouso (senior market access executive), and Roxanne Schwans‮…